Moderna and ILCM to collaborate in order to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 (CN-1)

Highlights

•  Both the companies are collaborating to develop mRNA-3351
•  CN-1is a rare disease caused due to mutation in gene UGT1A1

The Institute for Life Changing Medicines (ILCM) and the Moderna have announced their collaboration, to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type-1 (CN-1).

CN-1 is an ultra-rare disease, and there are only 70-1....